CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd, has announced positive top-line results from its Phase 3 clinical study of BP11, an investigational biosimilar to Xolair (omalizumab). Study meets primary endpoints in CSU patients According to the company, the study successfully met all primary endpoints, demonstrating high comparability with the reference […]